A Randomized, Placebo-Controlled, Double-Blind, Single-Dose, Phase 1 Study to Explore the PK/PD Relationship of QRL-101 in People Living With ALS
Latest Information Update: 07 Jan 2026
At a glance
- Drugs QRA 101 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors QurAlis Corporation
Most Recent Events
- 29 Dec 2025 Topline result data presented in the QurAlis Corporation Media Release.
- 02 Sep 2025 Status changed from recruiting to completed.
- 27 Mar 2025 Planned primary completion date changed from 10 Mar 2025 to 10 Nov 2025.